418 related articles for article (PubMed ID: 29438771)
1. Chronic inducible urticaria: A systematic review of treatment options.
Dressler C; Werner RN; Eisert L; Zuberbier T; Nast A; Maurer M
J Allergy Clin Immunol; 2018 May; 141(5):1726-1734. PubMed ID: 29438771
[TBL] [Abstract][Full Text] [Related]
2. Management of chronic inducible urticaria according to the guidelines: A prospective controlled study.
Kocatürk E; Can PK; Akbas PE; Copur M; Degirmentepe EN; Kızıltac K; Singer R
J Dermatol Sci; 2017 Jul; 87(1):60-69. PubMed ID: 28314658
[TBL] [Abstract][Full Text] [Related]
3. Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: an expert opinion.
Vestergaard C; Toubi E; Maurer M; Triggiani M; Ballmer-Weber B; Marsland A; Ferrer M; Knulst A; Giménez-Arnau A
Eur J Dermatol; 2017 Feb; 27(1):10-19. PubMed ID: 27882879
[TBL] [Abstract][Full Text] [Related]
4. Omalizumab treatment in patients with chronic inducible urticaria: A systematic review of published evidence.
Maurer M; Metz M; Brehler R; Hillen U; Jakob T; Mahler V; Pföhler C; Staubach P; Treudler R; Wedi B; Magerl M
J Allergy Clin Immunol; 2018 Feb; 141(2):638-649. PubMed ID: 28751232
[TBL] [Abstract][Full Text] [Related]
5. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis.
Metz M; Ohanyan T; Church MK; Maurer M
J Dermatol Sci; 2014 Jan; 73(1):57-62. PubMed ID: 24060603
[TBL] [Abstract][Full Text] [Related]
6. Comparison between chronic spontaneous urticaria and chronic induced urticaria on the efficacy of omalizumab treatment: A systematic review and meta-analysis.
He ZH; Qiu SC; Huang ZW; Zhang GQ; An QQ; Qu F; Wang N
Dermatol Ther; 2022 Dec; 35(12):e15928. PubMed ID: 36222320
[TBL] [Abstract][Full Text] [Related]
7. What are the effects of omalizumab in refractory chronic spontaneous urticaria?
López M; Navajas-Galimany L
Medwave; 2015 Dec; 15 Suppl 3():e6346. PubMed ID: 26731420
[TBL] [Abstract][Full Text] [Related]
8. Management of Chronic Spontaneous Urticaria in Routine Clinical Practice Following the EAACI/GA(2)LEN/EDF/WAO Guidelines.
Marín-Cabañas I; Berbegal-de Gracia L; de León-Marrero F; Hispán P; Silvestre JF
Actas Dermosifiliogr; 2017 May; 108(4):346-353. PubMed ID: 28219634
[TBL] [Abstract][Full Text] [Related]
9. Omalizumab in Chronic Urticaria: An Italian Survey.
Damiani G; Diani M; Conic RRZ; Colli L; Ferrucci S; Martina E; Offidani AM; Pigatto PDM
Int Arch Allergy Immunol; 2019; 178(1):45-49. PubMed ID: 30396176
[TBL] [Abstract][Full Text] [Related]
10. The Classification, Pathogenesis, Diagnostic Workup, and Management of Urticaria: An Update.
Maurer M; Zuberbier T; Metz M
Handb Exp Pharmacol; 2022; 268():117-133. PubMed ID: 34247278
[TBL] [Abstract][Full Text] [Related]
11. Omalizumab in chronic urticaria.
Metz M; Maurer M
Curr Opin Allergy Clin Immunol; 2012 Aug; 12(4):406-11. PubMed ID: 22766620
[TBL] [Abstract][Full Text] [Related]
12. How to Approach Chronic Inducible Urticaria.
Maurer M; Fluhr JW; Khan DA
J Allergy Clin Immunol Pract; 2018; 6(4):1119-1130. PubMed ID: 30033913
[TBL] [Abstract][Full Text] [Related]
13. Delayed Pressure Urticaria: Clinical and Diagnostic Features and Response to Omalizumab.
Veleiro-Pérez B; Alba-Muñoz J; Pérez-Quintero O; Rodríguez RL; Calvín-Lamas M; Parra-Arrondo A
Int Arch Allergy Immunol; 2022; 183(10):1089-1094. PubMed ID: 35609554
[TBL] [Abstract][Full Text] [Related]
14. Delayed Pressure Urticaria: A Systematic Review of Treatment Options.
Kulthanan K; Ungprasert P; Tuchinda P; Chularojanamontri L; Charoenpipatsin N; Maurer M
J Allergy Clin Immunol Pract; 2020 Jun; 8(6):2035-2049.e5. PubMed ID: 32179196
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study.
Ghazanfar MN; Holm JG; Thomsen SF
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1761-1767. PubMed ID: 29729103
[TBL] [Abstract][Full Text] [Related]
16. Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial.
Staubach P; Metz M; Chapman-Rothe N; Sieder C; Bräutigam M; Canvin J; Maurer M
Allergy; 2016 Aug; 71(8):1135-44. PubMed ID: 27010957
[TBL] [Abstract][Full Text] [Related]
17. Treatments of cold urticaria: A systematic review.
Kulthanan K; Hunnangkul S; Tuchinda P; Chularojanamontri L; Weerasubpong P; Subchookul C; Maurer M
J Allergy Clin Immunol; 2019 Apr; 143(4):1311-1331. PubMed ID: 30776418
[TBL] [Abstract][Full Text] [Related]
18. Symptomatic Dermographism: A Systematic Review of Treatment Options.
Kulthanan K; Ungprasert P; Tuchinda P; Chularojanamontri L; Rujitharanawong C; Kiratiwongwan R; Jantanapornchai N; Hawro T; Maurer M
J Allergy Clin Immunol Pract; 2020 Oct; 8(9):3141-3161. PubMed ID: 32473421
[TBL] [Abstract][Full Text] [Related]
19. Omalizumab in chronic spontaneous and inducible urticaria: a 9 year retrospective study in Portugal.
Marcelino J; Costa AC; Mendes A; Alonso E; Cabral Duarte F; Pedro E; Pereira-Barbosa M
Eur Ann Allergy Clin Immunol; 2018 Jul; 50(4):169-176. PubMed ID: 29479938
[No Abstract] [Full Text] [Related]
20. Omalizumab on Chronic Spontaneous Urticaria and Chronic Inducible Urticaria: A Real-World Study of Efficacy and Predictors of Treatment Outcome.
Jeong SH; Lim DJ; Chang SE; Kim KH; Kim KJ; Park EJ
J Korean Med Sci; 2022 Jul; 37(27):e211. PubMed ID: 35818702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
